CFGI’s Post

Ready to go public in the life sciences field? The process of getting from Point A to Point B in your IPO can be complex, with input from many different departments and stakeholders. Add on the extra regulations applying to life sciences companies, and it's clear: You need to approach this process in a careful, well-informed way. Fortunately, the CFGI team has created a step-by-step guide to taking your life sciences firm public: https://bit.ly/4bC199Q #CFGI #LifeSciences #IPO #GoingPublic

𝐀𝐫𝐞 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐏𝐎𝐬 𝐬𝐞𝐭 𝐟𝐨𝐫 𝐚 𝐫𝐞𝐬𝐮𝐫𝐠𝐞𝐧𝐜𝐞 𝐢𝐧 𝟮𝟬𝟮𝟰? Over the last two years, the biotech IPO scene has been relatively quite. Yet, a recent market upswing in the last quarter of 2023 hints at a potential revival of IPOs this year. The strong performance of biotech stocks last quarter, driven by the US Fed's stance on rates and notable mergers, suggests that unless a significant economic shock occurs, biotech stands to benefit from investors' increased risk appetite this year. It’s not likely that 2024 will mirror 2020 or 2021, the history of swift shifts in risk tolerance suggests the possibility of a substantial uptick in IPO activity. A great and insightful read from Richard Murphey and Bay Bridge Bio, check it out!

Discover the latest trends and 2024 outlook for life sciences deals involving European targets. Our publication delivers an overview of the European deals landscape including M&A, Venture Capital and IPO deal trends. Explore our full publication. #LifeSciences #Europe #Deals #MergersandAcquisitions #VentureCapital #IPO #KPMG #Pharmaceuticals

📊 Latest IPO GMP 🚀 1⃣ Juniper Hotels IPO, priced at 360, Shows a GMP of 0-0% signaling less potential gains! 📈✨ 2⃣ Gpt Healthcare IPO, priced at 186, shows a GMP of 19-10%, urging caution on returns. 🚨🤔 3⃣ Exicom Tele-Systems IPO, priced at 142, commands a stellar GMP of 97 - 68% promising exciting returns! 🚀 4⃣ Platinum Industries IPO, priced at 171, Shows a GMP of 34- 20% signaling less potential gains! 5⃣ Bharat Highways InvIT IPO, priced at 100, commands a stellar GMP of 0-0% promising exciting returns! 🌐🚀 6⃣ Mukka Proteins IPO, priced at TBA, commands a stellar GMP of 15 promising exciting returns! 🌐🚀 Stay on the pulse of the market for more updates! 🔍💼 Note:- it is only for educational purposes

📊 Latest IPO GMP 🚀 1⃣ Juniper Hotels IPO, priced at 360, Shows a GMP of 0-0% signaling less potential gains! 📈✨ 2⃣ Gpt Healthcare IPO, priced at 186, shows a GMP of 19-10%, urging caution on returns. 🚨🤔 3⃣ Exicom Tele-Systems IPO, priced at 142, commands a stellar GMP of 97 - 68% promising exciting returns! 🚀 4⃣ Platinum Industries IPO, priced at 171, Shows a GMP of 34- 20% signaling less potential gains! 5⃣ Bharat Highways InvIT IPO, priced at 100, commands a stellar GMP of 0-0% promising exciting returns! 🌐🚀 6⃣ Mukka Proteins IPO, priced at TBA, commands a stellar GMP of 15 promising exciting returns! 🌐🚀 Stay on the pulse of the market for more updates! 🔍💼 Note:- it is only for educational purposes

An important market trend to watch! #SPACs might never fully go away if the ambitions of three new healthcare-focused shops have any sway. As initial public offerings are far and few between, and even reverse mergers have fallen by the wayside, blank-check companies might fill a gap in the public markets, or so their sponsors are betting. Voyager Acquisition filed for a $261 million IPO on Tuesday, Sim Acquisition’s $200 million plans appeared on Monday and Launch One Acquisition’s paperwork for a $200 million debuted last week. All three wrote in their S-1 documents that they hope to carry a company in the healthcare industry onto the public markets. Launch One wrote that it’s particularly interested in “life sciences, globally.” #IPO #capitalmarket #publicmarket #healthcare #lifescience #lifesciences #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #publicofferings #VoyagerAcquisition #SimAcquisition #LaunchOne #biotech #biotechnology #biotechnews

As we enter 2024, private equity investors are poised for a dynamic year of mergers and acquisitions in the realm of "outsourced pharma services." Despite the seemingly unglamorous label, the sector has captured the attention of PE players, especially in Europe. With a robust pharma and life sciences sector and several PE-owned assets maturing, industry experts predict a surge in M&A activities. Medical communications agencies, specializing in services to commercialize new drugs, are taking centre stage. Notable players, such as UK-based Avalere Health (formerly Fishawack Health), are expected to make their way to the market in 2024, adding to the lineup of PE-owned businesses in this space. Even in the face of challenges experienced by debt markets in 2023, PE owned assets in the medical communications sector have displayed impressive growth, propelled by strategic initiatives. The sector's resilience and strategic positioning continue to make it an attractive destination for private equity investments. #PrivateEquity #PharmaServices #PEInsights

Excited to share my views on the IPO public markets for life sciences companies, recently published by PharmaVoice. The strong start has been hailed as a possible rebound for the industry, and it's a good start to the 2024 IPO class. However, I believe there's more work to be done to have a broader opening. As I mentioned in the article, my guidance is to "Survive to 25'." What are your thoughts? Check out the article here: https://lnkd.in/gGUNnZaw

IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial share sales. #ipo #biopharma #dealmaker #initialpublicoffering #capitalmarkets

**IPO Weekly Winners & Losers** =============== The IPO market saw a mixed performance in the last week. According to Renaissance Capital, a total of 24 companies went public, raising $4.3 billion. Here are the weekly winners and losers: **Winners:** * **Snowflake Inc. (SNOW)**: +14.1% first-day return, raising $3.4 billion * **Unity Software Inc. (U)**: +10.4% first-day return, raising $1.3 billion * **DocuSign Inc. (DOCU)**: +9.5% first-day return, raising $543.5 million **Losers:** * **Gossamer Bio Inc. (GOSS)**: -12.9% first-day return, raising $150 million * **G1 Therapeutics Inc. (GTHX)**: -6.4% first-day return, raising $125 million * **Linxon plc (LXN)**: -5.4% first-day return, raising $250 million These companies will be closely monitored in the coming weeks as investors assess their performance in the public market. Source: https://lnkd.in/gqUsETAA Update Date: 3 hours ago